한빛사논문
- 조회724
DaeYong Lee, Kristin Huntoon, Yifan Wang, Wen Jiang,* and Betty Y. S. Kim*
Dr. D. Y. Lee, Dr. K. Huntoon, Prof. B. Y. S. Kim
Department of Neurosurgery
The University of Texas MD Anderson Cancer Center
Houston, TX 77030, USA
Dr. Y. Wang, Prof. W. Jiang
Department of Radiation Oncology
The University of Texas Southwestern Medical Center
Dallas, TX 75390, USA
Dr. Y. Wang, Prof. W. Jiang
Department of Radiation Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX 77030, USA
*Corresponding author.
Abstract
The discovery of immune checkpoint blockade has revolutionized the field of immuno-oncology and established the foundation for developing various new therapies that can surpass conventional cancer treatments. Most recent immunotherapeutic strategies have focused on adaptive immune responses by targeting T cell-activating pathways, genetic engineering of T cells with chimeric antigen receptors, or bispecific antibodies. Despite the unprecedented clinical success, these T cell-based treatments have only benefited a small proportion of patients. Thus, the need for the next generation of cancer immunotherapy is driven by identifying novel therapeutic molecules or new immunoengineered cells. To maximize the therapeutic potency via innate immunogenicity, the convergence of innate immunity-based therapy and biomaterials is required to yield an efficient index in clinical trials. This review highlights how biomaterials can efficiently reprogram and recruit innate immune cells in tumors and ultimately initiate activation of T cell immunity against advanced cancers. Moreover, the design and specific biomaterials that improve innate immune cells’ targeting ability to selectively activate immunogenicity with minimal adverse effects are discussed.
논문정보
- Review Paper
- 2021년 05월 (BRIC 등록일 2021-06-02)
- 국외 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
